EMA Revoked: Adakveo (Crizanlizumab) — Novartis Europharm Limited

View source ↗

Summary

EMA has revoked Adakveo (crizanlizumab) marketed by Novartis Europharm Limited for sickle cell disease/anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)

Snippet

Status: Revoked. Therapeutic area: Anemia, Sickle Cell. MAH: Novartis Europharm Limited. Decision date: 03/08/2023. Conditional approval